Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Viridian Therapeutics, Inc. VRDN
$23.70
-$0.14 (-0.59%)
На 18:04, 12 мая 2023
+87.34%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1118891500.00000000
-
week52high
39.00
-
week52low
9.66
-
Revenue
1772000
-
P/E TTM
-8
-
Beta
0.97577800
-
EPS
-4.02000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Ladenburg Thalmann | Buy | Buy | 16 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 15 авг 2022 г. |
| B. Riley Securities | Buy | 23 июн 2022 г. | |
| JMP Securities | Market Outperform | Market Outperform | 11 мар 2022 г. |
| SVB Leerink | Outperform | 18 ноя 2021 г. | |
| JMP Securities | Market Outperform | Market Outperform | 15 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 09 янв 2023 г. |
| Needham | Buy | 19 дек 2022 г. | |
| Credit Suisse | Outperform | 16 дек 2022 г. | |
| HC Wainwright & Co. | Buy | 01 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Violin Jonathan | D | 430905 | 50000 | 02 февр 2023 г. |
| Meisner Lara | D | 20003 | 1872 | 23 янв 2023 г. |
| Meisner Lara | D | 39750 | 4971 | 23 янв 2023 г. |
| Meisner Lara | D | 0 | 6843 | 23 янв 2023 г. |
| Meisner Lara | A | 6843 | 1872 | 23 янв 2023 г. |
| Meisner Lara | A | 4971 | 4971 | 23 янв 2023 г. |
| Katz Barrett | D | 267000 | 24853 | 17 янв 2023 г. |
| Katz Barrett | D | 0 | 24853 | 17 янв 2023 г. |
| Katz Barrett | A | 24853 | 24853 | 17 янв 2023 г. |
| Katz Barrett | D | 291853 | 4147 | 13 янв 2023 г. |
Новостная лента
Why Viridian Therapeutics Is One Of My 2023 Top Picks
Seeking Alpha
25 янв 2023 г. в 13:14
Viridian was one of my top picks in 2022 and it made the 2023 list again. VRDN-001 data continue to impress and Viridian looks well-positioned to disrupt the thyroid eye disease market later this decade.
Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 08:00
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that its President and Chief Executive Officer, Jonathan Violin, Ph.D., will present an overview of the company along with its upcoming corporate priorities at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 2:15 p.m. PST / 5:15 p.m. EST in San Francisco, California.
MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge
Seeking Alpha
02 янв 2023 г. в 10:12
Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.
Viridian: Better Data Than A Blockbuster Competitor
Seeking Alpha
15 дек 2022 г. в 08:00
Viridian Therapeutics, Inc.'s data in TED beats Tepezza's trial data. Tepezza is a blockbuster drug.
Viridian Therapeutics, Inc. (VRDN) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 14:08
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants John Jordan - Vice President of Investor Relations Jonathan Violin - President & Chief Executive Officer Barrett Katz - Chief Medical Officer Kristian Humer - Chief Financial Officer & Chief Business Officer Conference Call Participants Rami Katkhuda - LifeSci Capital Gavin Clark-Gartner - Evercore ISI Thomas Smith - SVB Securities Laura Chico - Wedbush Securities Kalpit Patel - B. Riley Securities Jason Butler - JMP Securities Operator Greetings and welcome to Viridian Therapeutics Third Quarter 2022 Earnings Call.